检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孙燕 刘玉龙 何笑笑 方玉婷 SUN Yan;LIU Yulong;HE Xiaoxiao;FANG Yuting(The People′s Hospital of Yingshang,Fuyang,Anhui,China 236200;The First Affiliated Hospital of University of Science and Technology of China·Anhui Provincial Hospital,Hefei,Anhui,China 230001)
机构地区:[1]安徽省阜阳市颍上县人民医院,安徽阜阳236200 [2]中国科学技术大学附属第一医院·安徽省立医院,安徽合肥230001
出 处:《中国药业》2024年第24期47-51,共5页China Pharmaceuticals
基 金:安徽省阜阳市卫生健康科研项目[FY2023-140]。
摘 要:目的探讨医药协同管理模式对经皮冠状动脉介入治疗(PCI)术后危险因素控制的影响。方法选取安徽省阜阳市颍上县人民医院2020年1月至2021年11月接受PCI的患者180例,按随机数字表法分为观察组(医药协同管理模式)和对照组(仅医师管理),各90例。患者每月门诊随访1次,随访6个月。结果出院时两组患者各临床指标均无显著差异(P>0.05);随访6个月时,观察组低密度脂蛋白胆固醇达标率(75.56%比48.89%,P<0.001)、非高密度脂蛋白胆固醇达标率(64.44%比45.56%,P=0.011)、心率达标率(22.22%比6.67%,P=0.003)、β受体拮抗剂使用率(75.56%比53.33%,P=0.002)、血管紧张素转化酶抑制剂(或血管紧张素Ⅱ受体拮抗剂)使用率(77.78%比53.33%,P=0.001)及Morisky量表评分[(7.74±0.46)分比(7.11±0.77)分,P<0.001]均显著高于对照组。两组患者药品不良事件发生率无显著差异(2.22%比0,P>0.05)。结论医药协同管理可改善PCI术后患者的危险因素控制,提高患者的用药依从性。Objective To investigate the effect of physician-pharmacist collaborative management mode on the risk factor control in patients after percutaneous coronary intervention(PCI).Methods A total of 180 patients who underwent PCI at the People′s Hospital of Yingshang from January 2020 to November 2021 were selected and divided into the observation group(physician-pharmacist collaborative management mode)and the control group(physician management mode)by a random number table method,with 90 cases in each group.The patients were received follow-up visits once a month for six months.Results There was no significant difference in clinical indicators between the two groups at discharge(P>0.05).At the follow-up visits of six months,the standard-reaching rates of low-density lipoprotein cholesterol(LDL-C,75.56%vs.48.89%,P<0.001),non-high-density lipoprotein cholesterol(non-HDL-C,64.44%vs.45.56%,P=0.011)and heart rate(22.22%vs.6.67%,P=0.003),the use rates ofβ-receptor antagonist(75.56%vs.53.33%,P=0.002)and angiotensin converting enzyme inhibitor/angiotensinⅡreceptor blockers(ACEI/ARB,77.78%vs.53.33%,P=0.001)and Morisky Medication Adherence Scale score[(7.74±0.46)points vs.(7.11±0.77)points,P<0.001]in the observation group were significantly higher than those in the control group.There was no significant difference in the incidence of adverse events between the two groups(2.22%vs.0,P>0.05).Conclusion Physician-pharmacist collaborative management mode can improve the risk factor control and medication adherence in patients after PCI.
关 键 词:医药协同管理模式 经皮冠状动脉介入治疗 二级预防药物 危险因素 用药依从性
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.38